Recent developments in our understanding of neoplastic transformation and tumorigenesis have largely paralleled technical advances in molecular and cellular biology. A great deal of work has been focused in the past two decades upon tumour types which claim vast numbers yearly, for example, cancers of the breast, lung, colon, blood, and bone. However, many basic genetic aberrations first detected in these malignancies are apparently shared by a variety of tumours, which are perhaps less frequent, but no less devastating. This review article will attempt to focus on recent efforts to characterise genetically a number of neurological tumours, primarily focusing on astrocytomas and their malignant counterpart, glioblastoma. Where appropriate, we will also indicate relevant findings which have been reported for meningiomas and tumours associated with neurofibromatosis type 2 (bilateral acoustic neuroma). As a class of tumours which exert clinical effects largely through volume expansion in spatially confined compartments, and which do not metastasise to other organs, neurological tumours may represent an ideal system in which to study mechanisms of cell cycle control and transcriptional regulation involved in tumorigenesis. In addition, they may provide models for understanding the steps (40-60%) . Such EGFR amplification may also be frequently associated with amplification of N-ras.'0 As will be discussed below, our laboratory has recently shown a strong correlation between EGFR amplification and genetic loss of loci on chromosome 10, suggesting that a cooperative mechanism between such loci may underlie a subset of glioblastomas."1 On the basis of radiolabelled ligand binding it has also been suggested that EGFR may play a role in the generation of meningiomal2 and ependymoma."3 Finally, certain glioblastomas may also overexpress transforming growth factor alpha (TGF-a), which resembles EGF and binds the EGFR to stimulate tyrosine kinase activity.14 Basic fibroblast growth factor (bFGF) is known to exert a trophic effect upon a variety of cells of neural origin and is prevalent in neural tissue.'516 Human glioma cell lines express both an FGF-like activity and a bFGF binding receptor and proliferate in response to exogenously applied bFGF." It has also been suggested that in addition to a conventional autocrine role in tumorigenesis, bFGF may promote glial tumour growth by the stimulation of angiogenesis or neovascularisation."7 18 The human c-rosl gene, originally identified as the proto-oncogene mcf3 in NIH 3T3 transformation assays, ' Kinzler et aP3 have recently identified a cellular oncogene which was amplified and highly expressed in a human glioma, gli. Gli is a zinc finger transcription factor which resembles members of the Kruppel family of Drosophila gap segmentation genes.'4'5 Coexpression of Gli with the adenovirus ElA oncoprotein transforms primary cells which are then tumorigenic in nude mice, suggesting that Gli can be placed in a similar complement- '6 ation group as ras.
TUMOUR SUPPRESSOR GENES
A great deal of attention in recent years has been directed towards the potential role of tumour suppressor genes, or 'anti-oncogenes', in the aetiology of a variety of human cancers. These genes encode protein products which, when not expressed or when expressed only in mutant form, lead to a growth advantage which may produce a neoplastic phenotype. These proteins presumptively negatively regulate growth in normal cells. The genetic model for tumour suppressor genes originated with the study of the childhood cancer retinoblastoma, a hereditary ophthalmological tumour. Although DNA linkage analysis suggested dominant inheritance linked to chromosome 13q 14, subsequent analysis of tumour specimens showed characteristic lack of expression of the RB encoded message.'7 A large body of data has since indicated that RB does in fact follow a 'recessive' pattern requiring inactivation or mutation or both of both allelic copies for tumour formation, and that hereditary cases had suggested dominant inheritance because the high statistical probability of the 'second hit' in somatic cells produced a virtual 100% penetrance of the disease. This mechanism of germline inheritance of a genetic predis- 63 Finally, we are in the process of examining a number of potential candidate loci on chromosome 10, in particular the p34/cdc2 cell cycle associated kinase. Although our data are preliminary, four of seven glioblastomas express an altered cDNA for the p34/cdc2 kinase, suggesting that at least in some cases (all seven lost one copy of chromosome 10) this cell cycle regulatory protein may be a target for mutation in glioblastomas (R Chung, unpublished observations). We are actively characterising these aberrant proteins to determine their possible functional role in these tumours.
Conclusions
Neurological tumours represent an ideal model system in which to study specific genetic events and the interrelationships between such glioblastomas events which underly tumorigenesis. The quency than involvement of growth factors (PDGF, EGF, f 50 to 75% etc), signal transduction factors (N-ras, cent region of myc), and nuclear cell cycle regulatory proct, a number teins (p53, cdc2) parallels pathogenetic events ;ed with only seen in other human cancers, suggesting that, ay to surmise with time, neurological tumours will emerge as omosome 10 a well understood group of treatable malignangenesis, with cies ( figure) . The spectrum of growth charaction of both teristics shown by these tumours allows the 10 may be identification of stage specific genetic changes, instability in with the hope of directing therapeutic shown that in measures at those events specifically involved 72% showed in the progression of tumours currently incurowed EGFR able by conventional surgery, chemotherapies, iowever, was and radiotherapies. amplification
The techniques used in the genetic characggesting that terisation of neural tumours are no different related.," in from those used in the investigation of other and chromo-cancers. Recent advances have been aided not na.8586 These only by technical innovations, but perhaps more importantly by the realisation by neurosurgical and neuropathological staff of the importance of careful tumour handling (for example, liquid nitrogen snap freezing), the importance of departmental cell culture faciliExtSacellular ties, and the importance of obtaining blood samples as crucial controls for any genetic studies. As an increasing number of such departments recruit investigators trained in molecular and cellular biology, the understanding of these devastating tumours should rise exponentially. 
